HEXTEND AND PENTALYTE COLLABORATION AGREEMENT BETWEEN BIOTIME, INC. AND SUMMIT PHARMACEUTICALS INTERNATIONAL CORPORATIONCollaboration Agreement • December 30th, 2004 • Biotime Inc • Biological products, (no disgnostic substances) • California
The following are the terms, under which Summit Pharmaceuticals International Corporation, a corporation having its principal place of business at Confort Yasuda Bldg. 2-9, Kanda Nishiki-cho, Chiyoda-ku, Tokyo 101-0054, Japan (“Summit”), and BioTime, Inc., a California corporation having its principal place of business at 935 Pardee Street, Berkeley, California (“BioTime”), intend to collaborate to obtain regulatory approval for the marketing, sale, and use of BioTime products, Hextend and PentaLyte, for certain human therapeutic uses in Japan.
